BioSpace News Archive

“This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases,” commented Maria Maccecchini, Ph.D., CEO of Annovis.

Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 TG4050 : first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac ® technology – First data expected in 4Q 2021 TG4001 : expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data

Combining computational mining of big data with experimental testing in the lab, researchers at Children’s Hospital of Philadelphia have identified RNA editing events that influence gene expression and, in turn, the phenotypic manifestation of that expression.

The Academy of General Dentistry has named Colleen Lawler, CAE, IOM, as its new executive director.

Regulatory guidance anticipated in the first half of 2021 for registrational clinical development plan of investigational drug, rusfertide (PTG-300), for polycythemia vera

Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2020 and provided an update on key milestones.

Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that it will present new translational data at the 2021 American Association for Cancer Research Annual Meeting taking place virtually from April 10-15, 2021.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in two e-posters during AACR Annual Meeting 2021.

Atreca, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that a trial-in-progress poster will be presented at the virtual AACR Annual Meeting, which is being held over two one-week periods: April 10 – 15 and May 17 – 21 2021.